Advice for Life Sciences Companies Going Commercial for the First Time
By Jim Mackaness
Life sciences companies going commercial for the first time have the opportunity to create significant shareholder value – but the path to achieving this milestone will likely be volatile. The words that best sum up my advice to management teams and boards at life sciences companies that embark on the…Read More
Read MoreLatest Insights: 2023 Healthcare, Technology and Consumer Trends
By Laureen DeBuono
FLG Partners’ C-suite consulting and advisory practice supports a diverse continuum of industry sectors, from healthcare and life sciences to technology (SaaS and software to med tech and hardware) and consumer, from e-commerce to CPG. Our partners regularly attend many industry conferences and networking opportunities to stay abreast of the…Read More
Read MoreChanging Business Models: The CFO’s Role When Pivoting for Success
By Nancy Hargreaves
As a CEO, when a board member or investor questions the feasibility of your company’s business model, you might be tempted to counter with the pat response “if it ain’t broke, don’t fix it”. But what if your business model IS broken? What should you do then? I work frequently…Read More
Read MoreRaising Capital in Life Sciences in 2022-2023: What Works?
By Greg Curhan
Raising money in the capital markets for a biopharma or life sciences company over the last few years has been quite a roller coaster ride. Funding among U.S. biotech startups reached a record high of $77 billion in 2021 (Crunchbase), as investors were attracted to expanding opportunities in genetics, therapeutics…Read More
Read More